Literature DB >> 16193902

Neuromyelitis optica with hypothalamic involvement.

Alexandre Y Poppe1, Yves Lapierre, Denis Melançon, Diane Lowden, Lucy Wardell, Louise M Fullerton, Amit Bar-Or.   

Abstract

We describe two cases of neuromyelitis optica (NMO) with clinical and radiographically confirmed features of hypothalamic involvement, in the absence of other parenchymal brain lesions. Their course is otherwise typical of Devic's form of NMO. A review of the literature identifies additional cases of NMO in which clinical features attributable to under-recognized dysfunction of the hypothalamic-pituitary axis were present. We propose that the currently accepted criteria for the diagnosis of NMO could be revisited to recognize the possibility of lesions developing within hypothalamic structures.

Entities:  

Mesh:

Year:  2005        PMID: 16193902     DOI: 10.1191/1352458505ms1200cr

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  26 in total

1.  Multiple organ injury associated with neuromyelitis optica spectrum disorder in a low-grade B-cell lymphoma suspected of being follicular lymphoma.

Authors:  Shoko Nakayama-Ichiyama; Taiji Yokote; Nobuya Hiraoka; Kazuki Iwaki; Ayami Takayama; Kichinosuke Kobayashi; Toshikazu Akioka; Satoko Oka; Takuji Miyoshi; Shimon Ishida; Takayuki Takubo; Motomu Tsuji; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2010-11-02       Impact factor: 4.849

2.  Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype.

Authors:  G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-18       Impact factor: 10.154

3.  Successful treatment of a hypothalamic lesion in neuromyelitis optica by plasma exchange.

Authors:  Shohei Watanabe; Ichiro Nakashima; Isabelle Miyazawa; Tatsuro Misu; Yusei Shiga; Yoichi Nakagawa; Kazuo Fujihara; Yasuto Itoyama
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

4.  Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study.

Authors:  M Nakamura; I Miyazawa; K Fujihara; I Nakashima; T Misu; S Watanabe; T Takahashi; Y Itoyama
Journal:  J Neurol       Date:  2008-02-04       Impact factor: 4.849

Review 5.  Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder.

Authors:  Dominique Rosales; Ilya Kister
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

Review 6.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

7.  Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.

Authors:  B F Gh Popescu; V A Lennon; J E Parisi; C L Howe; S D Weigand; J A Cabrera-Gómez; K Newell; R N Mandler; S J Pittock; B G Weinshenker; C F Lucchinetti
Journal:  Neurology       Date:  2011-03-02       Impact factor: 9.910

8.  Longer T(2) relaxation time is a marker of hypothalamic gliosis in mice with diet-induced obesity.

Authors:  Donghoon Lee; Joshua P Thaler; Kathryn E Berkseth; Susan J Melhorn; Michael W Schwartz; Ellen A Schur
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

Review 9.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

Review 10.  Conventional and advanced imaging in neuromyelitis optica.

Authors:  Y Barnett; I J Sutton; M Ghadiri; L Masters; R Zivadinov; M H Barnett
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-13       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.